about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Sarep­ta was stunned by the re­jec­tion of Vyondys 53. Now it's stun­ning every­one with a sur­prise ac­cel­er­at­ed ap­proval

6 years ago
R&D
FDA+

As­traZeneca joins Mer­ck, Bris­tol-My­ers in Chi­na's check­point race as reg­u­la­tors OK first PD-L1

6 years ago
China
Pharma

Al­pham­ab On­col­o­gy rounds out HKEX's sec­ond biotech IPO year with $230M raise and high lo­cal in­ter­est

6 years ago
Financing
China

De­sert­ed by Astel­las and Mer­ck, lit­tle Cor­re­vio still can't win over FDA pan­el con­cerned with its AFib drug's safe­ty

6 years ago
R&D

Af­ter sev­er­al high pro­file start­up launch­es, om­niv­o­rous Omega Funds clos­es $438M fund to pur­sue more deals

6 years ago
Financing

Am­gen puts its foot down in shiny new South San Fran­cis­co hub as it re­or­ga­nizes R&D ops

6 years ago
R&D
Pharma

Cel­lar­i­ty, Flag­ship's $50M bet on net­work bi­ol­o­gy, mar­ries ma­chine learn­ing and sin­gle-cell tech for drug dis­cov­ery

6 years ago
Startups

Game on: Re­gen­eron's BC­MA bis­pe­cif­ic makes clin­i­cal da­ta de­but, kick­ing off mul­ti­ple myelo­ma matchup with ...

6 years ago
R&D

New Sanofi CEO Hud­son adds next-gen can­cer drug tech to the R&D quest, buy­ing Syn­thorx for $2.5B

6 years ago
Deals

UCB buffs up in block­buster pso­ri­a­sis race as bimek­izum­ab beats Hu­mi­ra in head-to-head

6 years ago
R&D

With FDA re­view of its gene ther­a­py un­der­way, Fer­ring's $570M spin­out de­liv­ers in PhI­II blad­der can­cer read­out

6 years ago
R&D
Cell/Gene Tx

Skep­tics pounce as Bio­gen de­tails pos­i­tive sub­group analy­sis on ad­u­canum­ab — and both sides are dig­ging in

6 years ago
R&D

Michael Ehlers teas­es plan to build the next 'sig­na­ture' ge­net­ic med­i­cine com­pa­ny with $75M from Ap­ple Tree Part­ners

6 years ago
R&D

Aca­dia un­veils the pos­i­tive PhI­II it's tak­ing to FDA for ex­pand­ing Nu­plazid's use in psy­chosis

6 years ago
R&D

Ea­ger to tout piv­otal win, Omeros how­ev­er keeps key pa­ra­me­ters shroud­ed

6 years ago
R&D

Roche moves deep­er in­to Mer­ck ter­ri­to­ry with Tecen­triq/chemo OK in front­line NSCLC

6 years ago
Pharma

Bio­gen boasts PhII win in lu­pus — will any­one turn their head from Alzheimer's to no­tice?

6 years ago
R&D

On the heels of $225M roy­al­ty deal, Ko­di­ak shoots for $250M raise to fund piv­otal pro­grams of its Eylea slay­er

6 years ago
Financing

In­cyte nabs pri­or­i­ty re­view for bile duct can­cer drug; Temasek shows in­ter­est in an­oth­er Wood­ford dar­ling — re­port

6 years ago
News Briefing

Agios taps Bris­tol-My­ers vet Bruce Car to re­place re­tir­ing CSO

6 years ago
People

Shak­ing up Chi­na's PD-(L)1 re­im­burse­ment land­scape, In­novent, Eli Lil­ly earn cov­et­ed spot on na­tion­al cov­er­age

6 years ago
China
Pharma

Mass Gen­er­al team presents mouse da­ta to back the case for us­ing re­for­mu­lat­ed asth­ma drug to treat ALS

6 years ago
Discovery

J&J, Te­va and four oth­ers un­der crim­i­nal probe as feds in­ves­ti­gate opi­oid mak­ers for fail­ing to mon­i­tor dis­tri­b­u­tion

6 years ago
Pharma

With mo­men­tum from FDA OK, SK Bio­phar­ma to breath new life in­to Ko­re­an biotech with $850M IPO — re­port

6 years ago
Financing
First page Previous page 85868788899091 Next page Last page
A service from the Financial Times